In 2015, the PPARα/γ agonist, saroglitazar, was reported to be of substantial benefit for patients with atherogenic dyslipidemia and/or diabetes (56), and in 2017 therapy with statin plus K-877 (pemafibrate) was advocated as therapy with a favorable benefit-to-risk ratio (57). Here, PPARA is linked to metabolic syndrome.